Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- A Backlog Of Decisions Is Building At The FDA
Nov 07, 2008 11:48 AM
- Ahead Of The Fed
Aug 04, 2008 10:48 AM
- Periodicals Wrap-Up for Monday, August 4th
Aug 04, 2008 09:49 AM
- Biotechs Jump On IMCL
Jul 31, 2008 03:12 AM
- Few Thoughts and a Look at the Earnings in the Coming Week
Jul 28, 2008 01:20 AM
- Oil Falls, Financials Jump!
Jul 09, 2008 02:27 AM
- Another Failed Rally
Jul 08, 2008 06:06 AM
- Periodicals Wrap-Up for Friday, May 30th
May 30, 2008 10:04 AM
- Savient Looking At All Options For Value, Including Sale
May 05, 2008 06:40 PM
- Savient Pharmaceutical: Pegloticase Program Will Meet Review Criteria
Apr 21, 2008 07:51 AM
- Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
Nov 19, 2008 07:01 AM
- Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
Nov 13, 2008 04:30 PM
- Beacon Equity Issues Technical Trade Alerts on Market Movers: INCY, QLTI, LINTA, PDGI, FRPT, SVNT
Nov 10, 2008 09:03 AM
- Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
Nov 06, 2008 05:05 PM
- Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Nov 05, 2008 07:05 PM
- Savient Submits Biologics License Application (BLA) for pegloticase
Oct 31, 2008 08:59 AM
- Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Oct 27, 2008 08:30 AM
- Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
Oct 24, 2008 04:05 PM
- Savient to Host Conference Call on Pegloticase Scientific Presentations
Oct 14, 2008 04:06 PM
- Savient Provides Update on Business Development Plans and BLA Filing
Sep 26, 2008 08:01 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
SVNT
|
Compare to S&P
|
| YTD |
-83.94 %
|
-63.84 %
|
| 4 Weeks |
-69.07 %
|
-65.61 %
|
| 12 Weeks |
-83.35 %
|
-73.54 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 28.89 %
|
|
EPS Growth in Last Year: -14.29 %
|
|
Sales Growth in Last Quarter: 53.54 %
|
|
Sales Growth in Last Quarter: -78.99 %
|
|
|
